Drug interactions
Griseofulvin + Linagliptin-metformin
Severity: Minor
Griseofulvin and Linagliptin-metformin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Griseofulvin is a weak inducer of CYP3A4 and may lower exposure to linagliptin, which could reduce glycemic control. The legacy direction (increased levels) is incorrect for an inducer. The effect is probably modest.
What this interaction means in plain words
Griseofulvin and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Griseofulvin belongs to Anti Fungals; Linagliptin-metformin belongs to Endocrine.
Why it happens
Possible weak induction of CYP3A4 and P-glycoprotein by griseofulvin, increasing linagliptin clearance.
What to do
Monitor blood glucose and HbA1c when griseofulvin is started or stopped. Adjust antidiabetic therapy if control worsens.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Griseofulvin and Linagliptin-metformin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Griseofulvin
Frequently asked questions
Can I take Griseofulvin with Linagliptin-metformin?
MediHelp rates the interaction as minor. Griseofulvin and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Griseofulvin is a weak inducer of CYP3A4 and may lower exposure to linagliptin, which could reduce glycemic control. The legacy direction (increased levels) is incorrect for an inducer. The effect is probably modest.
How serious is the interaction between Griseofulvin and Linagliptin-metformin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose and HbA1c when griseofulvin is started or stopped. Adjust antidiabetic therapy if control worsens.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
